Source ARM Atara Biotherapeutics Announces Pricing of $150M Public OfferingJuly 18, 2019 – (Atara Biotherapeutics) – The offering is expected to close on or about July 23, 2019, subject to customary closing conditions. MilliporeSigma and Broad Institute Announce CRISPR License Framework to Encourage InnovationJuly 18, 2019 – (MilliporeSigma) – MilliporeSigma and the Broad Institute of MIT and Harvard
The Alliance for Regenerative Medicine (ARM) and UK BioIndustry Association (BIA) released a collaborative report offering an in-depth look at ATMP sector trends and metrics in the UK. The report details industry-specific statistics compiled from 56 cell therapy, gene therapy, tissue engineering, and other ATMP developers headquartered in the UK, including total financings, partnerships and other deals, clinical
Harnessing light and genetics, the approach illuminates and modulates the activity of neurons, enables study of brain function and behavior, sets stage for optogenetic therapies The 2019 Warren Alpert Foundation Prize has been awarded to four scientists for pioneering work in the field of optogenetics, a revolutionary technique that uses light and genetic modification to
Source https://www.nature.com/articles/s41584-019-0255-1 Injuries to articular cartilage and menisci can lead to cartilage degeneration that ultimately results in arthritis. Different forms of arthritis affect ~50 million people in the USA alone, and it is therefore crucial to identify methods that will halt or slow the progression to arthritis, starting with the initiating events of cartilage and
Since both myocardium and vasculature in the heart are excessively damaged following myocardial infarction (MI), therapeutic strategies for treating MI hearts should concurrently target both so as to achieve true cardiac repair. Here we demonstrate a concomitant method that exploits the advantages of cardiomyocytes derived from human induced pluripotent stem cells (hiPSC-CMs) and human mesenchymal
The advancement of adoptive cell immunotherapy and the impressive clinical outcomes obtained targeting hematologic malignancies with CAR-T cells dictate for further developments towards a broader use of cellular therapeutics for more patients and more types of malignancy. The advent of iPSC technology provides new perspectives for the manufacturing of customized, tumor-targeting T/NK cells, with improved
tem cell therapies have the potential to treat many conditions, but so far there’s little proof that they do. Even so, clinics around the world offer stem cell-based treatments for a host of medical problems. New research warns that some of these treatments might not be effective and can, in fact, cause harm — sometimes
Source NIH Researchers continue to make progress with cancer immunotherapy, a type of treatment that harnesses the body’s own immune cells to attack cancer. But Kole Roybal wants to help move the field further ahead by engineering patients’ immune cells to detect an even broader range of cancers and then launch customized attacks against them.
Source PMLive Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking CAR-T therapy for the first patient in Europe, and how the centre of excellence has adapted to make precision medicine a reality Dr
Many of the efforts to improve on the first generation of CAR-T therapies such that they can reach solid tumors had focused on tweaks inherent to the cancer killing agent — specifically, utilizing more potent T cells as their base, from stem memory T cells to virally associated T cells to marrow infiltrating lymphocytes. But
